ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Trimodality Therapy Improves Survival In Early Disease

January 27, 2006

Lasker Awards Resume; ASCO Fall Conference Scheduled For October

September 21, 1990

Four Center Grants In Danger; Shingleton to Retire, Owen Promoted At Hopkins

January 9, 1987

Nobel Laureate Gilman Prepares to Leave The Texas Cancer Agency—Can it Survive?

September 28, 2012

In Brief: Ford Named Acting Deputy Director, DCPC; Foundation Leads Oncology Administrators

June 3, 1994

House Passes 2.8 Percent Increase For NCI

December 11, 2009